Cabaletta Bio, Inc., was incorporated under the laws of the State of Delaware in April 2017. The company is a clinical-stage biotechnology company focused on discovering and developing engineered T-cell therapies that have the potential to provide a deep and durable, perhaps therapeutic, treatment for patients with autoimmune diseases.
